Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, ...
We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharma ...
Zacks Investment Research on MSN
Will lower Gardasil sales hurt MRK's vaccines sales in Q1 earnings?
Merck MRK continues to encounter persistent challenges with its second-largest product, Gardasil, a vaccine approved to ...
Zacks.com on MSN
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock
The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...
New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results